JAB-3068 is the second SHP2 inhibitor approved by the FDA to enter clinical development. JAB-3312, the second generation SHP2 inhibitor designed by Jacobio has more potent anti-tumor activities. Both compounds have been granted orphan drug designation by the FDA for the treatment of esophageal cancer (including esophageal squamous cell carcinoma).
Therapy | Indications | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|
KRAS G12Ci Combination Therapy | KRAS G12C mut NSCLC |
|
Phase IIa initiated Jul 2022 |
|
Combo w/EGFRi | Osimertinib progressed NSCLC |
|
FPI Jan 2022 |
|
Combo w/PD-1 mAb | NSCLC, HNSCC, ESCC |
|
Phase IIa FPI Feb 2022 |
|
Mono | BRAF Class 3/NF1 LOF mutant solid tumors |
|
Closed to enrollment |
Therapy | Indications | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|
Mono | ESCC, HNSCC, NSCLC, ACC |
|
Closed to enrollment | |
Combo w/PD-1 mAb | ESCC, HNSCC, NSCLC |
|
Glecirasib (JAB-21822) is a KRAS G12C inhibitor independently developed by Jacobio. From the in-house preclinical head-to-head study, this compound has superior oral bioavailability and systemic drug exposure, better pharmacokinetic profiles and tolerance, and is a potential best-in-class compound.
Therapy | Indications | Phase I | Phase IIa | Pivotal | Recent progress |
---|---|---|---|---|---|
Mono | NSCLC |
|
Pivotal study FPI Sep 2022 BTD granted Dec 2022 |
||
Mono | CRC, PDAC and other solid tumors |
|
Phase IIa FPI Mar 2022 |
||
Mono | NSCLC, CRC |
|
Phase II does expansion Initiated Sep 2022 |
||
Mono | 1L NSCLC with STK11 co-mutation |
|
FPI in China Sep 2022 |
||
Combo w/SHP2i JAB-3312 | NSCLC, CRC and other solid tumors |
|
FPI May 2022 |
||
Combo w/EGFR mAb | CRC |
|
FPI Feb 2023 |
||
Combo w/PD-1 mAb | NSCLC |
|
JAB-8263 class 1 innovative drug that is a Bromodomain and Extra-Terminal motif (BET) inhibitor independently developed by Jacobio. Preclinical studies have shown that JAB-8263 can effectively inhibit tumor growth at very low concentrations. In addition to solid tumors, hematological tumors are particularly sensitive to JAB-8263. Patients with hematological tumors and some types of solid tumors may benefit from the treatment of JAB-8263.
Therapy | Indications | IND | Phase I | Phase II | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
|||
Monotherapy | Solid Tumor |
|
FPI Feb 2022 |
||
Monotherapy | MF, AML |
|
FPI Apr 2021 |
JAB-2485 is an Aurora Kinase A (AURKA) inhibitor developed independently by Jacobio Pharma. It inhibits AURKA effectively and does not affect the activity of other kinases structurally similar to AURKA, minimizing the toxicity of the drug and improving the therapeutic window.
Therapy | Indications | IND | Phase I | Phase II | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
IND Approved in China Oct 2022 FPI in U.S. Jan 2023 |
JAB-BX102 is a humanized anti-CD73 monoclonal antibody (mAb)developed by Jacobio to inhibit the enzymatic activity of CD73. CD73 is the key node of adenosine pathway, and its inhibitors have broad therapeutic prospects for tumors dependent on adenosine pathway. Relevant studies have shown that adenosine promotes SHP2 phosphorylation, suggesting that anti-CD73 antibody can be combined with SHP2 inhibitor, which is also developed by Jacobio to benefit patients with advanced solid tumors.
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Mono and Combo w/ PD-1 antibody | Solid Tumor |
|
FPI in China Sep 2022 |
JAB-24114 is Jacobio’s self-developed GUE (glutamine-utilizing enzyme) inhibitor. Tumor growth is highly dependent on glutamine, which can be converted into various metabolites by multiple glutamine-utilizing enzymes (GUEs). These metabolites support a variety of tumor growth pathways. JAB-24114 can inhibit multiple GUEs, leading to simultaneous blockade of multiple glutamine metabolism pathways, with great therapeutic potential. Compared with its similar product, JAB-24114 has a wider therapeutic window. JAB-24114 has the distinctive combination effects of depleting tumors of nutrients while enhancing T cell function. Synergistic action with anti-PD-(L)1 can boost the anti-tumor effect. JAB-24114 can also be used in combination with SHP2 inhibitors or KRAS inhibitors.
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
IND Approved in China Mar 2023 |
JAB-BX300 is Jacobio’s self-developed LIF mAb. LIF is an important biomarker in pancreatic ductal adenocarcinoma (PDAC). Studies show that, LIF plays a crucial role in KRAS-driven cancer models and the blockade of LIF by antibodies represents an attractive approach to improving therapeutic outcomes. LIF is an attractive target for the treatment of KRAS-driven tumors, which has potential to combo with KRAS and SHP2 inhibitors.
Therapy | Indications | IND | Phase I | Phase IIa | Recent progress |
---|---|---|---|---|---|
Monotherapy | Solid Tumor |
|
IND Approved in China Apr 2023 |
Asset | Target | Modality | IND Schedule | Indications | Recent Development | Lead Optimization | IND-enabling |
---|---|---|---|---|---|---|---|
JAB-26766 | PARP7 (I/O) |
Small molecule | 2023 IND | Solid tumors | Candidate nominated, entering into IND enabling studies in Jan 2022 |
|
|
JAB-23400 | KRASmulti (RAS pathway) |
Small molecule | 2023 IND | PDAC, CRC, NSCLC | Candidate nominated, entering into IND-enabling studies in 2022 |
|
|
JAB-30300 | P53 Y220C (P53 pathway) |
Small molecule | 2023 IND | Solid tumors | Candidate nominated, entering into IND enabling studies in Jul 2022 |
|
|
JAB-BX400 | HER2-STING (I/O) |
iADC | - | Solid tumors | - |
|
|
JAB-X1800 | CD73-STING (I/O) |
iADC | 2024 IND | Solid tumors | Candidate nominated in 2023 Q1 |
|
|
JAB-22000 | KRAS G12D (RAS pathway) |
Small molecule | 2024 IND | PDAC, CRC, NSCLC | - |
|
Abbreviation: mAb = monoclonal antibody; ESCC = esophageal squamous cell carcinoma; HNSCC = head and neck squamous cell carcinoma; NSCLC = non-small cell lung cancer; KRAS amp = KRAS amplification; LOF = loss of function; CRC = colorectal cancer; MF = myelofibrosis; AML = acute myeloid leukemia; CRPC = castration resistant prostate cancer; HCC = hepatocellular carcinoma; PDAC = pancreatic ductal adenocarcinoma; IND = investigational new drug.
As date of Apr 4, 2023